2020
DOI: 10.21203/rs.3.rs-24076/v2
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

Stigmasterol Sensitizes Endometrial Cancer Cells to Chemotherapy By repressing Nrf2 Signal Pathway

Abstract: Background: Chemoresistance reduces the 5-year survival rate of endometrial cancer patient, which is the current major obstacle for cancer therapy. Increasing evidence state that Nrf2 contributes to chemoresistance in several kinds of cancer. However, its role in endometrial cancer cells remains unclarified. Methods: Immunohistochemistry staining was used to detect the expression of Nrf2 in normal patient and endometrial cancer patient. Stable transfection Ishikawa cell line with high level of Nrf2 was establi… Show more

Help me understand this report
View published versions

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
references
References 23 publications
(33 reference statements)
0
0
0
Order By: Relevance